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LETTERS
Generalized
Vaccinia 2 Days
after Smallpox
Revaccination
To the Editor: Hospital and public
health personnel are currently receiv-
ing smallpox vaccination in a national
effort to increase preparedness for a
possible deliberate release of small-
pox (1). Generalized vaccinia (GV) is
a typically self-limited adverse event
following vaccination (incidence
23.4–238.2 cases per million primary
vaccinees and 1.2–10.8 cases per mil-
lion revaccinees) (2,3). 
We report the clinical course and
laboratory diagnosis of GV in a 37-
year-old woman with a history of at
least one uncomplicated childhood
inoculation that left a vaccination scar.
She was revaccinated on March 12,
2003. Before revaccination, the patient
reported no contraindications to vacci-
nation and denied any conditions that
typically weaken the immune system
(including HIV/AIDS, leukemia, lym-
phoma, other cancers, radiation,
chemotherapy, organ transplant, post-
transplant therapy, immunosuppres-
sive medications, severe autoimmune
disease, and primary immune defi-
ciency). The patient also confirmed
that she did not have a skin disease or
a history of eczema or atopic dermati-
tis, nor was she pregnant or allergic to
a vaccine component. 
On March 14, some 44 hours after
vaccination, the patient reported
headache, chills, pruritus, chest pain
(described as chest “heaviness”),
recurrent vomiting, and maculopapu-
lar lesions. The lesions, characterized
by the patient as “mosquito bites,”
first appeared on the face, then the
legs, and then the trunk and upper
extremities. Maximum oral tempera-
ture was 37.7°C. Over the next 4 days,
approximately 30 pustules developed,
several of which began to drain.
Nausea persisted, and the patient had
a stiff neck and recurring chest tight-
ness, but physical examination,
echocardiography, electrocardiogra-
phy, and chest radiography results
were within normal limits. By March
25, the patient’s lesions had all
scabbed, the scabs had fallen off, and
she felt well enough to return to work.
Pustular material obtained on March
18 from two unroofed lesions on the
shoulder (Figure) and back tested pos-
itive at the Wadsworth Center-
Axelrod Institute, New York State
Department of Health, for vaccinia
virus DNA by a TaqMan (Applied
Biosystems, Foster City, CA) real-
time polymerase chain reaction assay
provided by the Laboratory Response
Network, Centers for Disease Control
and Prevention. The presence of
ortho-poxvirus was confirmed by
electron microscopy of lesion fluid. 
This case is the first report of a lab-
oratory-confirmed case of GV among
recent civilian vaccinees and is
notable for the GV occurrence in a
revaccinee. GV was not reported
among 132,656 military personnel
recently revaccinated (4). A single
case of GV in a revaccinee among
38,514 recent civilian vaccinations (5)
yields a ratio that exceeds the rate in
revaccinees observed in earlier
reports and the difference would be
even greater if civilians who received
primary vaccinations were excluded.
This laboratory confirmation of
GV demonstrates the potential of lab-
oratory testing to determine the cause
of a post-vaccination rash. Possible
cases of GV in earlier surveillance
efforts represented a mixed group of
rashes, some of uncertain etiology (6).
This patient’s clinical course is
notable for the onset of GV 2 days
after vaccination, as compared to a
mean of 9 days (range 1–20+) after
(generally primary) vaccination (2)
and suggests that viremia can occur
quickly after vaccination. 
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Salmonella 
enterica Serovar
Enteritidis, Japan
To the Editor: Nontyphoidal sal-
monellae are the important causative
agents of foodborne diseases in Japan
and other industrialized countries.
Salmonella enterica serovar Enter-
itidis has risen to the leading cause of
infection among Salmonella spp.
since 1989 (1). Emergence of drug-
resistant S. Enteritidis has been rarely
reported while S. Typhimurium,
another serovar of major public health
concerns, has been reported to acquire
multidrug resistance such as DT104
resistance to ampicillin, chloram-
phenicol, streptomycin, sulfonamide,
and tetracycline (R-ACSSuT) (2). 
We previously reported outbreaks
caused by strains resistant to ampi-
cillin and streptomycin (resistance
type R-AS, herein); the strains’ reac-
tions against the phages used in bacte-
riophage typing did not conform to
any known reaction patterns (phage
type [PT] RDNC-a, herein, with the
following reactions: (-) for #3, 5–7,
11–13, 15, and 16 phages; (+++) for
#2 phage; opaque lysis [OL] for #4
and  9 phages; <OL for #10 phage;
and ambiguous reactions (-/+++) were
observed for #1, 8, and 14 phages)
(3). To investigate the characters of
the R-AS strains more extensively, we
surveyed isolates from outbreaks that
occurred from 1997 to 2002 for
antimicrobial drug susceptibility and
bacteriophage typing. 
S. Enteritidis strains from 899 out-
breaks that occurred from 1997 to
2002 were tested. Bacteriophage typ-
ing was done according to the Public
Health Laboratory Service (PHLS),
London, United Kingdom guidelines
(4). Antimicrobial drug susceptibility
testing was done with a disc diffusion
method on Mueller-Hinton II agar
(Becton Dickinson Microbiology
Systems, Cockeysville, MD) as previ-
ously described (5). Antimicrobial
drugs used in this study were ampi-
cillin, streptomycin, tetracycline,
kanamycin, nalidixic acid, gen-
tamycin, sulfamethoxazole-trimetho-
prim, trimethoprim, chloramphenicol,
cefotaxim, and ciprofloxacin.
Dominant phage types were PT4
(36.9%) and PT1 (26.9%). They have
been dominant among outbreak-rela-
ted strains since 1992 (1). Other types
were also identified at certain fre-
quencies. For example, RDNC-a,
PT47, PT6, PT6a, and PT21 account-
ed for 4.4%, 5.3%, 4.0%, 3.2%, and
2.0% of the phage types, respectively.
Strains sensitive to all the antimi-
crobial drugs tested were the most
predominant (55.1%), followed by
those resistant to only streptomycin
(34.8%). R-AS was the third most
predominant, accounting for 4.1%. A
correlation existed between drug
resistance and phage types in that all
the R-AS strains (n = 37) showed
RDNC-a in bacteriophage typing, and
all the RDNC-a strains (n = 40) were
resistant to at least ampicillin includ-
ing two R-A and one R-AST strains. 
Since previous studies described
the correlation between drug resist-
ance and phage types as a result of
acquisition of an R-plasmid (6), we
focused on the relationship between
RDNC-a and ampicillin resistance.
Plasmid profiles analysis of the
RDNC-a strains showed that all but
one (R-AST) had at least two kinds of
plasmids, and all but one were
approximately 50 kb and 60 kb in
size. The last could be the so-called
serovar-specific plasmid (7). Southern
blot analysis by using the ampicillin
resistance gene of pBluescript KS (+)
(Stratagene, La Jolla, CA) as a probe
indicated that a resistance gene was
carried on the 50-kb plasmid.
Furthermore, when Escherichia coli
DH10B cells (Invitrogen Corporation,
Carlsbad, CA) were transformed with
plasmids isolated from an RDNC-a R-
AS strain and plated onto Luria broth
plates containing 100 mg/L of ampi-
cillin, the 50-kb, but not 60-kb, plas-
mid could be isolated from the ampi-
cillin-resistant transformants. And the
50-kb plasmid from the transformants
was hybridized to the probe for ampi-
cillin resistance described above.
Thus, the 50-kb plasmid of RDNC-a
R-A or -AS strains was suggested to
be an R-plasmid responsible for ampi-
cillin resistance.
A representative 50-kb plasmid
(p981123) was prepared from the
DH10B transformant cells described
earlier for further characterization.
Southern blot analysis suggested that
a 6-kb EcoRI fragment contained the
resistance determinant. Sequences for
the fragment were analyzed done by
using ABI PRISM 310 sequencer and
BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied
Biosystems, Foster City, CA). The
resulting sequence showed high simi-
larities to Pseudomonas aeruginosa
Tn801 (accession no. AF080442; 98%
identical) and E. coli Tn3 (accession
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